United-Imaging-Logo

Molecular Imaging: Page 2

New PET tracer show promise in neuroblastoma
By Will Morton
F-18 mFBG achieved a pooled sensitivity of 97%, compared with 82% for I-123 MIBG.
July 9, 2026
Cancer Target
PET/MRI can reduce the need for biopsies in prostate cancer
By Will Morton
Prostate biopsies are associated with considerable morbidity, including pain, rectal bleeding, prostatitis, and urinary tract infections.
July 2, 2026
A visual abstract of the study.
GE HealthCare, University Hospital Essen open nuclear medicine center
By AuntMinnieEurope.com staff writers
The center features the first installation of GE HealthCare's StarGuide GX SPECT/CT scanner.
July 1, 2026
Ge
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
Novel SST2-PET tracer shows promise in patients with NETs
By Will Morton
With a half-life of 3.3 hours, cyclotron-produced Cu-61 NODAGA-LM3 could allow delayed imaging and centralized distribution.
June 25, 2026
Maximum intensity projections showing biodistribution of Cu-61 NODAGA-LM3 (146 MBq) in a patient with a metastatic non-functional NET of the pancreas G2 (Ki-67: 5%) with lymph node, hepatic, osseous, and peritoneal as well as ovarian metastases. PET performed a 1-hour, 3-hours, and 18-hours post-injection show high and prolonged tumor uptake and excellent image contrast, with low uptake in the liver, intestinal tract, and other non-target organs.
PET RANO gains visibility as neurotheranostics research advances
By Claudia Tschabuschnig
Standardized PET response assessment, emerging theranostic targets, and new strategies to overcome the blood-brain barrier are among the developments shaping neuro-oncology research.
June 24, 2026
Prof. Nathalie Albert of Ludwig Maximilian University of Munich, member of the EANM Oncology & Theranostics Committee and Scientific Chair of the NMN Symposium.
As theranostics advances, access challenges remain across Europe
By Claudia Tschabuschnig
Theranostics is advancing rapidly, but access remains uneven across Europe. According to Prof. Clemens Decristoforo, differences in national regulations and healthcare systems continue to influence patient access to innovative radiopharmaceuticals.
June 24, 2026
Prof. Clemens Decristoforo is a member of the EANM Policy & Regulatory Affairs Council and professor at the Department of Nuclear Medicine at the Medical University of Innsbruck.
Six European societies launch RLT Referral Pathways Project
By Claudia Tschabuschnig
Radioligand therapy has proven itself clinically for advanced prostate cancer. What hasn't caught up is Europe's healthcare infrastructure.
June 23, 2026
Radiology and nuclear medicine are converging on clinical audit and quality frameworks across Europe.
$9M grant invests in 'next generation' of CAA scientists
By AuntMinnie.com staff writers
Project will combine advanced brain imaging with new molecular biomarkers and innovative experimental models.
June 19, 2026
Dollars Pile
PET/CT could improve margin assessment for breast tumors
By Amerigo Allegretto
Specimen PET/CT imaging outperforms routine intraoperative margin assessment in breast tumors.
June 19, 2026
Pet Scan Patient 400 (1)
Siemens Healthineers announces U.K. radiopharmacy expansion in Dunstable
By AuntMinnieEurope.com staff writers
Investment supports increased output and same-day delivery of PET radiopharmaceuticals and theranostics agents.
June 16, 2026
Dunstable Exterior Final Enhanced Upscaled 4x
Early FAPI-PET scans match 60-minute scans for lung cancer staging
By Will Morton
By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.
June 10, 2026
PET/CT images performed at 10- and 60-minutes following injection of Ga-68 FAPI-46 (mean 181 MBq; range 143–225 MBq).
Previous Page
Page 2 of 129
Next Page